arrow_back Back Filing freshness 10-Q FY 2023 SEC EDGAR

AXIM BIOTECHNOLOGIES, INC.

AXIM
— Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
11 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
58
Health
Fair
Bullish
auto_awesome

Analytical Summary

AXIM BIOTECHNOLOGIES, INC. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —
Dividend Yield —
Revenue Growth 345.3% ↗
Op. Margin —
ROIC 35.9% ↘
FCF / Share —
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

11-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$39.52K
↑ +345.3% —
Net Income Profit after all expenses
$-8.06M
↓ -29.1% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns ↑
99
Financial Health ↓
23
Cash Quality ↓
24

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 11 years · 44 quarters